It’s time to treat Non-24 with HETLIOZ® (tasimelteon)

HETLIOZ® (tasimelteon) demonstrated significant decreases in daytime sleep duration and increases in nighttime sleep duration, as compared to placebo1

  • In SET, a 6-month study to measure the safety and efficacy of tasimelteon, the circadian period of patients was measured at the end of the first month1
HETLIOZ (tasimelteon) Efficacy Clinical Data – SET HETLIOZ (tasimelteon) Efficacy Clinical Data – SET
  • Patients treated with HETLIOZ® experienced a 2-fold reduction in total daytime sleep vs placebo, during the 25% worst days when patients were most symptomatic1
  • During the 25% worst nights of sleep, patients treated with HETLIOZ® experienced a 2-fold increase in total nighttime sleep vs those who received placebo1

Study design—SET: A 6-month, Phase 3, randomized, double-masked, placebo-controlled, multicenter trial. Totally blind patients with Non-24 (N=84) who had non-entrained melatonin circadian rhythms were randomized to receive HETLIOZ® 20 mg (n=42) or placebo (n=42).1,2

SET, Safety and Efficacy of Tasimelteon.

HETLIOZ® clinical trial program: 2 pivotal, Phase 3, multicenter, randomized, double-masked, placebo-controlled trials in patients who are totally blind with Non-24 1,2

  • Efficacy assessments were based on the 25% of nights with the least nighttime sleep and the 25% of days with the most daytime sleep
  • Patients were more symptomatic when sleep-wake cycles were most misaligned with the 24-hour day

Study 1: SET2

Graphic of Study 1 design (SET), a 6-month, double-masked trial with 42 patients on HETLIOZ (tasimelteon) 20 mg versus 42 patients on placebo Safety & Efficacy of Tasimelteon HETLIOZ

References: 1. HETLIOZ® [prescribing information]. Vanda Pharmaceuticals Inc. 2014. 2. Data on file. Vanda Pharmaceuticals Inc. 2014.

Important Safety Information

The most common adverse reactions (incidence >5% and at least twice as high on HETLIOZ® (tasimelteon) than on placebo) were headache, increased alanine aminotransferase, nightmares or unusual dreams, and upper respiratory or urinary tract infection. The risk of adverse reactions may be greater in elderly (>65 years) patients than younger patients because exposure to HETLIOZ® is increased by approximately 2-fold compared with younger patients.

Indication

HETLIOZ® is indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Important Safety Information

  • HETLIOZ® may cause somnolence: After taking HETLIOZ®, patients should limit their activity to preparing for going to bed, because HETLIOZ® can potentially impair the performance of activities requiring complete mental alertness.
  • The most common adverse reactions (incidence >5% and at least twice as high on HETLIOZ® than on placebo) were headache, increased alanine aminotransferase, nightmares or unusual dreams, and upper respiratory or urinary tract infection. The risk of adverse reactions may be greater in elderly (>65 years) patients than younger patients because exposure to HETLIOZ® is increased by approximately 2-fold compared with younger patients.
  • Use of HETLIOZ® should be avoided in combination with fluvoxamine or other strong CYP1A2 inhibitors, because of a potentially large increase in exposure of HETLIOZ®, and a greater risk of adverse reactions. HETLIOZ® should be avoided in combination with rifampin or other CYP3A4 inducers, because of a potentially large decrease in exposure of HETLIOZ®, with reduced efficacy.
  • There are no adequate and well-controlled studies of HETLIOZ® in pregnant women. Based on animal data, HETLIOZ® may cause fetal harm. HETLIOZ® should be used during pregnancy only if the potential benefit justifies the potential risks. Caution should be exercised when HETLIOZ® is administered to a nursing woman.
  • HETLIOZ® has not been studied in patients with severe hepatic impairment and is not recommended in these patients.
  • Safety and effectiveness of HETLIOZ® in pediatric patients have not been established.

Please see full Prescribing Information.